NKGen Biotech, Inc.: debt financing — NKGen Biotech issues 2.6M shares to Kepos in warrant exercise and downside settlement

NKGen Biotech, Inc.

Kepos exercised 555,555 warrants on a cashless basis, receiving 555,555 shares of NKGen common stock.
In lieu of $509,555 cash downside consideration, Kepos accepted 2,038,220 shares at $0.25/share; 2,593,775 total shares issued.
Outstanding $382,222 downside cash from prior reset to be satisfied with 1,528,888 shares at $0.25/share (future issuance).
Shares are unregistered, bear restrictive legends, and may only be transferred under Rule 144 or other registration exemption.

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.7

NKGen Biotech, Inc. incurred debt with Kepos Alpha Master Fund L.P..

Counterparty: Kepos Alpha Master Fund L.P.
Event: incurrence

Exact text from the filing

the Company issued to Kepos a total of 2,593,775 shares of common stock, consisting of the Warrant Shares and the Additional Shares

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001213900-25-038427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.